Novo Nordisk and reMYND, a spin-off contract research organization from the University of Leuven in Belgium, have signed a license agreement to further develop reMYND’s ReS39, a therapeutic for treating diabetes.

reMYND’s ReS39 is designed to sustain and increase the endogenous insulin production capacity of the pancreas by restoring beta-cell function and insulin signaling in Type 1 and Type 2 diabetes animal models.

Under the agreement, reMYND could receive up to EUR 350 million ($412 million) in research and milestone payments, plus royalties on resulting net sales.

Source: reMYND